With modern treatment, people with Marfan syndrome can expect to live into their early 70s, and in many cases their lifespan is now nearly equal to that of the general population. This is a dramatic improvement from just a few decades ago, when the median survival was only 48 years. The shift is largely due to better heart imaging, preventive medications, and planned surgical repair of the aorta before it becomes dangerous.
How Life Expectancy Has Changed Over Time
In 1972, the median survival for someone with Marfan syndrome was roughly 32 years. By 1993, that number had jumped to 72 years, an increase of more than 25%. Three advances drove most of that gain: blood pressure medications that slow aortic enlargement, routine imaging to monitor the aorta before problems develop, and elective surgical repair that replaces a weakened section of the aorta under controlled conditions rather than in an emergency.
Today, longevity for diagnosed and treated patients is described as “almost similar” to the general population. That qualifier matters. Cardiovascular complications remain the leading cause of death, accounting for roughly 60 to 80 percent of Marfan-related mortality. Most of those deaths occur in people who were never diagnosed or who were diagnosed too late for treatment to help. Men with Marfan syndrome also have a significantly lower life expectancy than women, though the reasons aren’t fully understood.
Why the Aorta Is the Central Risk
Marfan syndrome is caused by a mutation in the gene that produces fibrillin-1, a protein that gives connective tissue its strength and elasticity. When this protein is defective, the walls of the aorta (the body’s largest artery) gradually weaken and stretch. Over time, the aortic root, the section closest to the heart, can balloon outward into an aneurysm. If the aneurysm tears, it causes an aortic dissection, a life-threatening emergency where blood forces its way between the layers of the artery wall.
This process is slow in most people, which is why regular monitoring can catch it early. The aorta typically enlarges by less than half a millimeter per year in treated patients. But without monitoring, the first sign of trouble can be the dissection itself, and that’s where the survival statistics get grim.
Medications That Slow Aortic Growth
Two classes of blood pressure medication form the backbone of Marfan management. Beta-blockers reduce both heart rate and the force of each heartbeat, lowering the mechanical stress on the aortic wall. A large meta-analysis of randomized trials found that beta-blockers cut the rate of aortic root enlargement roughly in half compared to no treatment.
Angiotensin receptor blockers (commonly losartan) work through a different pathway, targeting a signaling molecule that contributes to the weakening of connective tissue. In the same pooled analysis, patients on these medications saw their aorta grow by about 0.38 mm per year compared to 0.52 mm per year in untreated patients. That difference of 0.14 mm per year may sound small, but compounded over a decade or more, it can mean the difference between needing surgery at 35 or at 55, or not at all.
When researchers compared the two drug classes head to head, the results were essentially equivalent. Neither showed a clear advantage over the other in slowing aortic growth, and both are considered reasonable first-line options. Some patients take both.
When Surgery Becomes Necessary
Elective aortic root replacement is recommended when the aorta reaches 5.0 cm in diameter. That threshold drops to 4.5 cm if there’s a family history of aortic dissection or the aorta is growing more than 5 mm per year. For pregnant patients, surgery may be considered at even smaller diameters because of the added cardiovascular demands of pregnancy.
The distinction between planned and emergency surgery is significant. Elective aortic root replacement carries an operative mortality of roughly 3 to 5 percent. Five-year survival after the procedure is about 93 percent, and 10-year survival is around 85 percent. Patients who had a planned repair before dissection occurred fared considerably better over the long term than those who needed emergency surgery after a tear. Chronic aortic dissection, where the tear has been present for some time before repair, carried roughly five times the risk of late death compared to surgery done before any dissection.
About 12 percent of patients needed a second operation within five years, and nearly 30 percent needed one within 10 years. These reoperations typically address new areas of aortic weakness that develop over time, which is why lifelong imaging surveillance continues even after a successful repair.
Exercise and Daily Life
Physical activity guidelines for Marfan syndrome remain conservative. Current recommendations limit exercise to low-intensity activities like walking, golf, bowling, and light cycling. The concern is straightforward: vigorous exercise raises blood pressure, and elevated pressure increases stress on a weakened aortic wall. A commonly used safety cutoff is keeping systolic blood pressure below 160 mmHg during activity.
Animal studies have shown that exercise at 75 to 85 percent of maximum capacity can trigger aortic aneurysms, while moderate intensity (55 to 65 percent of maximum) does not. Human data is limited, but the precautionary approach makes sense given what’s at stake. Importantly, moderate activity appears to be safe and beneficial. The restriction is on intensity, not on movement itself.
Pregnancy and Aortic Risk
Pregnancy increases blood volume and cardiac output, which adds strain to the aorta. For women with Marfan syndrome whose aortic root is under 40 mm, the risk of dissection during pregnancy is roughly 1 percent or less. When the aortic root exceeds 40 mm, that risk jumps to around 10 percent. Most pregnancy-related dissections occur in the third trimester or shortly after delivery.
Women who have already had aortic root replacement face a more complex picture. In one review, 7 of 24 women (about 29 percent) with prior root replacement experienced a pregnancy-related dissection, typically in a different section of the aorta than the one that was repaired. This underscores why close cardiovascular monitoring throughout pregnancy is essential for anyone with the condition.
Why Early Diagnosis Matters Most
The single biggest factor separating a near-normal lifespan from a shortened one is whether the diagnosis happens before the aorta is damaged beyond repair. People who are identified early, started on medication, monitored with regular imaging, and offered surgery at the right time can expect decades of active life. The survival gap that still exists is concentrated almost entirely in those who slip through without a diagnosis, often because their features are mild or because the condition wasn’t recognized in their family.
Certain genetic factors can influence severity. Mutations in specific regions of the fibrillin-1 gene (particularly exons 25 and 26) are associated with earlier and more severe disease, especially when diagnosed in infancy. But for the vast majority of people diagnosed in childhood or adulthood, the prognosis depends far more on consistent medical management than on which specific mutation they carry.